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Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development 
of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome 
Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide 
a prognostic model of HGS-OvCa classification, named “Classification of Ovarian Cancer” (CLOVAR). We 
validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst 
outcome group, accounting for 23% of all cases, was associated with a median survival of 23 months and a 
platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rate of 23% 
in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual dis-
ease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in 
urgent need of more effective therapies. The spectrum of outcomes observed here and their association with 
CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR 
model in the context of additional prognostic variables may provide a rationale for optimal combination of 
patient and treatment regimens.
Introduction
High-grade serous ovarian carcinoma (HGS-OvCa) accounts for 
60%–80% of the approximately 26,000 women diagnosed with epi-
thelial ovarian carcinoma in the US annually (1, 2). Known risk 
determinants for the development of ovarian carcinoma include 
BRCA1/BRCA2 mutations, family history, nulliparity, oral contra-
ceptive use, tubal ligation, pregnancy, and lactation (1, 3). A com-
mon treatment regimen consists of tumor debulking, followed by 
administration of platinum and taxane-based chemotherapy (4). 
The advanced stage at which most patients present, combined 
with the high rate of relapse, results in a 5-year survival rate less 
than 40% (5, 6). Identification of nonresponders and patients with 
primary platinum resistance (recurrence less than 6 months after 
last chemotherapy cycle) is an important step toward achieving 
greater life expectancy for serous ovarian carcinoma patients (7). 
Gene expression profiles have been established that are associated 
with overall survival (8, 9), debulking status (10), and response to 
platinum therapy (11–15). Despite those encouraging develop-
ments, no biomarkers for prediction of response to therapy are 
yet in clinical use.
Gene expression–based outcome predictors have had the great-
est impact in breast cancer, where gene signature–based assays of 
recurrence, chemotherapy efficacy, and metastasis were developed 
with the potential to guide therapy decisions (16–18). Predictors of 
prognosis have been developed for other cancers, but have not nec-
essarily led to changes in clinical practice. In addition to predicting 
survival, the potential of prognostic classifiers lies in the ability to 
recognize categories of patients that are more likely to respond 
to particular therapies. For example, the Mesenchymal expres-
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sion subtype of glioblastoma is being investigated in relation to 
response to angiogenesis inhibitors such as bevacizumab (19).
In a recent report from The Cancer Genome Atlas (TCGA) 
Research Network, 489 cases of HGS-OvCa were analyzed using 
copy number, expression and methylation arrays, and exonic 
sequencing of more than 18,500 genes (20). The HGS-OvCa 
genome was shown to harbor more somatic copy number altera-
tions and fewer gene mutations than glioblastoma, which was 
also studied by TCGA (21). Consistent with a recent report (22), 
96.5% of ovarian cases studied by TCGA contained a mutation in 
TP53 while also harboring a large number of copy number altera-
tions, with the major target genes including CCNE1, MYC, TERT, 
and NF1. The TCGA analysis additionally described 4 expression 
subtypes of HGS-OvCa. Based on the expression of marker genes, 
these subtypes were termed “Differentiated,” “Immunoreactive,” 
“Mesenchymal,” and “Proliferative” (23). A supervised prognostic 
signature based on 193 genes developed using 215 TCGA expres-
sion profiles was able to classify a validation set of 524 expression 
profiles into a group with a better predicted prognosis (median 
survival, approximately 48 months) and a group with a worse pre-
dicted prognosis (median survival, approximately 36 months).
Here, we expanded the description of the 4 recently identified 
signatures of HGS-OvCa using the full catalog of TCGA genomic 
and clinical data. We integrated subtype and prognostic classi-
fiers defined in a set of 489 expression profiles into a prognostic 
framework termed “Classification of Ovarian Cancer” 
(CLOVAR) and tested its accuracy in predicting out-
come on a dataset of 879 publicly available expression 
profiles of HGS-OvCa.
Results
Gene expression profiles from individual HGS-OvCa tumor 
samples exhibit features of multiple subtype signatures. It was 
previously reported that a portion of ovarian tumor 
samples are characterized by high numbers of infil-
trating T lymphocytes or stromal cells and that such 
tumor samples can be recognized by expression profil-
ing (23, 24). Using immunohistochemistry, we identi-
fied an increased number of samples with infiltrating 
T lymphocytes in the Immunoreactive group (42% 
[n = 19] vs. 16% [n = 80]; P < 0.01, Fisher exact test), 
whereas desmoplasia, associated with infiltrating 
stromal cells, was found more often in the Mesen-
chymal cluster, with borderline significance (27% 
[n = 26] vs. 12% [n = 63]; P = 0.07, Fisher exact test). To 
investigate the possibility that tumor samples express-
ing the Immunoreactive and Mesenchymal signatures were addi-
tionally expressing the non–infiltrating cell–associated Differen-
tiated or Proliferative signature, we used single-sample gene set 
enrichment analysis (ssGSEA) to assess gene set activation scores 
for all 489 tumor samples. ssGSEA is a rank-based comparison of 
the expression levels of genes in the gene set with all other genes in 
an expression profile. In this analysis, expression profiles cluster-
ing with, for instance, the Differentiated group will have a high 
Differentiated signature score. Signatures of the 4 subtypes were 
described previously (20). To define ssGSEA score cutoffs for 
inclusion in the set of samples expressing a subtype signature, we 
first assessed the silhouette width for each clustered profile. The 
silhouette width is defined as the ratio between the smallest cor-
relation between a profile and all other profiles within its clus-
ter and the largest correlation between that profile and all other 
profiles outside its cluster. The minimum ssGSEA score among 
samples that defined the original clusters and that clustered with 
a positive silhouette width to establish the ssGSEA score was used 
as cutoff value for inclusion into a subtype set. In this analysis, 
82% of the 489 expression profiles were assigned to at least 2 sub-
types (Figure 1 and Supplemental Table 1; supplemental material 
available online with this article; doi:10.1172/JCI65833DS1). For 
comparison, a similar analysis on our previously reported subtypes 
of glioblastoma (25) assigned 24% of expression profiles to more 
than 1 class (Supplemental Figure 1). Every possible signature 
Figure 1
HGS-OvCa signature ssGSEA scores. ssGSEA scores 
for 489 HGS-OvCa tumor samples were generated using 
4 previously described gene expression signatures (20): 
differentiated (D), immunoreactive (I), mesenchymal 
(M), and proliferative (P). (A) Binary scores indicating 
whether a tumor sample activates the gene signature. 
Each column represents 1 sample; each row represents 
1 gene signature. Red, activated; black, not activated. (B) 
Raw gene set activation scores. Each column represents 
1 sample; each row represents 1 gene signature. (C) 
Scatter plots and r2 values (numbers within plots) for all 
gene set combinations.
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combination was observed in at least 1 tumor sample, and nega-
tive correlations were observed between the Immunoreactive and 
Proliferative signatures (r2 = –0.81) and between the Differentiated 
and Mesenchymal signatures (r2 = –0.57). The overlap in gene sig-
nature scores suggests that HGS-OvCa does not consist of mutu-
ally exclusive expression subtypes, but that each tumor sample is 
represented by multiple signatures at different levels of activation. 
This pattern may reflect a higher level of homogeneity than is seen 
in other tumor types, such as glioblastoma and breast cancer.
Characterization of gene expression signatures. To assess whether 
the 4 HGS-OvCa subtype expression signatures were associated 
with specific genomic aberrations, we investigated whether gene 
set activation scores were significantly increased in altered versus 
nonaltered samples. Genes with alterations in more than 3% of 
samples were included in the analysis (copy number alterations, 
n = 489; mutation events, n = 316). After Benjamini-Hochberg cor-
rection of gene set score t test P values for multiple testing, no gene 
mutation or copy number deletion resulted in a significant change 
of gene set score. Copy number amplifications of 367 genes, map-
ping to 13 different commonly amplified regions, were found to 
be associated with a significant increase of activation levels of at 
least 1 of the 4 ovarian cancer signatures (Supplemental Table 2). 
To gain further insight into the possible target of amplification 
for the 13 amplification regions, we calculated Pearson correlation 
coefficients among 279 amplified genes with matching expression 
data and gene set activation scores. Of 11 genes with matching 
expression data at 1q32.1, LAD1, which regulates stability of epi-
thelial layer stability with mesenchyme, showed a correlation with 
the Differentiated gene set that was distinctly higher than other 
genes. When linking 105 genes at the 19q13 locus with expres-
sion levels to the Proliferative signature, we found NOTCH3 to be 
among the most highly correlated. NOTCH3 inactivation in sam-
ples expressing the Proliferative signature may provide a therapeu-
tic opportunity (26). The 12q14 gene whose expression correlated 
most highly with the Proliferative gene set was HMGA2, which sug-
gests a role for this chromatin-modifying gene that has previously 
been related to progression in lung adenocarcinoma (27). Ampli-
fication of the transcription factor MYC was associated with a sig-
nificant difference in Differentiated and Immunoreactive gene set 
scores, but correlation was much higher with Differentiated than 
with Immunoreactive signature scores.
The gene signatures were further characterized by correlat-
ing signature activation scores to the activation scores of 7,565 
gene sets from the Molecular Signatures Database (http://www.
broadinstitute.org/msigdb/; ref. 28) and gene expression levels (see 
Supplemental Methods).
Predicting outcome using an integrated signature classifier. We previ-
ously described a transcriptional signature of 193 genes predic-
tive of overall survival, which was developed using univariate Cox 
regression analysis on the expression profiles of 215 HGS-OvCa 
samples (20). In order to maximize the discovery power of the 
TCGA dataset, we used all 481 TCGA HGS-OvCa–derived expres-
sion profiles with matching clinical data, rather than the 215 pro-
files used in our previous work (20). To generate the new signature, 
we selected the 100 genes whose expression was most correlated 
(good prognosis genes, n = 47), or anticorrelated (poor progno-
sis genes, n = 53), with survival (Supplemental Table 3). We chose 
a signature of 100 genes to prevent sensitivity to overfitting of 
the data and to permit analysis of new samples with a medium-
throughput expression assay. We named this signature the “Classi-
fication of Ovarian Cancer” (CLOVAR) survival signature. Gene set 
enrichment analysis of the 100-gene CLOVAR survival signature, 
which includes genes such as RB1, NFKBIB, and RXRB, showed an 
overlap between the signature and Molecular Signatures Database 
gene sets such as BENPORATH_MYC_MAX_TARGETS and LY_
AGING_OLD_UP (Supplemental Table 4). Of the 100 genes in the 
CLOVAR survival signature, 36 were included from our recently 
reported 193-gene survival signature (20).
To verify the prognostic power of the CLOVAR survival signa-
ture, we used ssGSEA to analyze 64 TCGA expression profiles not 
included in the training dataset and 815 expression profiles with 
matching survival annotation from 6 published studies (9, 10, 23, 
29–31). CLOVAR survival signature ssGSEA scores were calculated 
for each of the 7 validation datasets. The validation cohort includ-
ed data generated on 5 different expression platforms, and the 
scale of the ssGSEA scores was dependent on the total number of 
genes included in the expression platform used. To make ssGSEA 
scores comparable between different expression platforms, scores 
were converted to a [0,1] scale within each dataset (see Methods). 
The validation set was stratified into CLOVAR poor prognosis or 
CLOVAR good prognosis groups using a cutoff score of 0.5. The 
difference in survival between the 2 prognostic groups was highly 
statistically significant (P < 0.0001; Figure 2A).
A significant difference in recurrence-free survival was observed 
between patients in the TCGA cohort whose tumor samples 
expressed either the Immunoreactive or the Mesenchymal signa-
ture (Supplemental Figure 2). Next, we set out to verify this sur-
vival characteristic in the validation cohort. As reducing the size 
of the signature allows for the use of medium-high throughput 
gene expression quantification systems, we first reduced the 4 
subtype signatures from 800 genes to gene signatures that, com-
bined, contained 100 genes. We refer to these herein as CLOVAR 
subtype signatures. The CLOVAR subtype signatures classified the 
TCGA cohort into the 4 groups used to define the signatures with 
a cross-validation error rate of 8%, which indicates that the origi-
nal clustering was captured by the reduced signatures. In order to 
determine whether validation cohort samples expressed the sub-
type signatures, we assessed ssGSEA scores of CLOVAR subtype 
signatures in the TCGA expression dataset. The minimum ssGSEA 
score among core samples was used to establish the ssGSEA score 
used as a cutoff value for inclusion into a subtype set. Using these 
ssGSEA cutoff values, tumor samples in the validation cohort were 
identified as expressing the CLOVAR Immunoreactive or CLO-
VAR Mesenchymal signatures. Cases expressing both signatures 
were assigned to a class according to the higher of the 2 scores. 
Those samples that did not express one of the signatures related 
to infiltrating cells were assigned to the CLOVAR Proliferative, 
CLOVAR Differentiated, CLOVAR Immunoreactive, or CLOVAR 
Mesenchymal class depending on the highest normalized gene set 
score for the 4 CLOVAR gene set signatures. Kaplan-Meier analy-
sis revealed a highly significant difference in survival among the 
4 validation set expression groups established by this approach 
(P < 0.0001; Figure 2B).
To combine the CLOVAR survival and CLOVAR subtype signa-
tures for outcome prediction, we established a multiple covariate 
model using the TCGA dataset and including 3 signature scores 
as variables: CLOVAR survival, CLOVAR Immunoreactive, and 
CLOVAR Mesenchymal. In this model, CLOVAR survival was the 
dominant variable (Supplemental Table 5). Based on this model 
with CLOVAR survival and CLOVAR subtype as covariates, we 
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computed risk scores of patients in training and validation sets. 
Patients in each set were then classified into good, intermediate, 
and poor outcome groups according the risk scores, using tertiles 
of risk scores for the TCGA set as cutoffs. We used this model to 
compute risk scores and classified the validation set (n = 879) into 
good, intermediate, and poor outcome groups, which showed 
5-year survival of 55%, 38%, and 29%, respectively. Next, we tested 
whether including additional prognostic factors could improve 
the predictions. CLOVAR survival, CLOVAR Immunoreactive, 
and CLOVAR Mesenchymal scores, stage, grade, residual disease, 
and age annotation were available on 428 TCGA patients, which 
were used to calibrate a model (Supplemental Table 5). Using this 
extended model, we classified 328 patients from the validation 
set for which these parameters were available. The 5-year survival 
of the good, intermediate, and poor outcome groups using the 
extended model was 60%, 39%, and 27%, respectively. Lastly, we 
tested whether addition of “presence of BRCA1/BRCA2 germline 
mutations” to the model could further inform prognostic clas-
sification. BRCA1/BRCA2 germline data were available for 273 
patients in the TCGA set and 83 patients in the validation set. 
The 5-year survival of the good, intermediate, and poor outcome 
groups in the validation set using the extended model including 
BRCA1/BRCA2 germline mutations was 61%, 25%, and 0%, respec-
tively. To compare the performance of the 3 models, we computed 
likelihoods for the TCGA and validation sets using high/inter-
mediate/low classification as a covariate, only including samples 
with nonmissing data on all variables (TCGA, n = 273; validation 
set, n = 83; Figure 3). Both in the TCGA set, which was used to 
train the models, and in the validation set, the extended model 
combined with BRCA1/BRCA2 germline mutation status showed 
the highest likelihood, suggesting most accurate performance in 
outcome prediction. Although the comparison may be hampered 
by the specific set of cases for which the correct annotation was 
available, this result suggests that a model combining CLOVAR 
Figure 2
Survival per CLOVAR subtype, CLOVAR survival class, and double classifiers. Kaplan Meier curves for CLOVAR survival class (A), survival per 
CLOVAR subtype (B), and double classification of samples by both CLOVAR subtype and CLOVAR survival signature (C). Data represent survival 
capped at 60 months for 879 samples in the validation set. (D) A further significant difference in survival was observed between optimally and 
suboptimally debulked CLOVAR Mesenchymal/CLOVAR poor prognosis patients.
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survival, CLOVAR Immunoreactive, and CLOVAR Mesenchymal 
scores and BRCA1/BRCA2 germline mutation status provides opti-
mal outcome predictions.
As BRCA1/BRCA2 germline mutation status was only available 
for 9.4% of samples in the validation set, we sought to further opti-
mize outcome prediction through combination of the CLOVAR 
survival and CLOVAR subtype signatures. We performed Kaplan-
Meier survival analysis between samples with CLOVAR poor prog-
nosis and CLOVAR good prognosis survival signatures within 
each of the CLOVAR Immunoreactive, CLOVAR Mesenchymal, 
CLOVAR Proliferative, and CLOVAR Differentiated subtypes. 
Importantly, the CLOVAR survival classifier predicted outcome 
with high significance within each of the 4 CLOVAR subtype 
groups (Figure 2C). The worst outcome was found in patients 
with tumors classified as both CLOVAR Mesenchymal and CLO-
VAR poor prognosis, which represented 23% of the validation set 
and showed a median overall survival of 23 months. The hazard 
ratio for death within 5 years of diagnosis for this group compared 
with the remainder of the sample cohort was 1.95 (95% confidence 
interval, 1.59 to 2.40), and the hazard ratio for recurrence within 
12 months was 1.66 (95% confidence interval, 1.26 to 2.18) (Sup-
plemental Table 6). Of the CLOVAR Mesenchymal/CLOVAR poor 
prognosis cases, 63% were determined to be resistant to platinum 
therapy, defined as having tumor recurrence within 6 months after 
the end of platinum therapy (Supplemental Table 1 and Supple-
mental Figure 3). All other samples — those not classified as CLO-
VAR Mesenchymal/CLOVAR poor prognosis — showed a plati-
num resistance rate of 23%. To refine the classification, we sought 
to understand those CLOVAR Mesenchymal/CLOVAR poor 
prognosis patients that had a relatively favorable outcome, with 
greater than 12 months progression-free survival (PFS). Germline 
BRCA1/BRCA2 mutations are associated with increased response 
rates to chemotherapy and overall survival (32). However, germline 
BRCA1/BRCA2 mutations were not found more frequently among 
tumor samples predicted as CLOVAR Mesenchymal/CLOVAR 
poor prognosis with greater than 12 months PFS compared with 
those CLOVAR Mesenchymal/CLOVAR poor prognosis samples 
with less than 12 months PFS. Similarly, such patients were not 
Figure 3
Survival analysis of multiple covariate outcome predictions. A multiple covariate proportional hazards model was trained using (A) only CLOVAR 
survival and CLOVAR subtype signatures; (B) CLOVAR survival and CLOVAR subtype signatures, stage, grade, age, and residual disease; or 
(C) CLOVAR survival and CLOVAR subtype signatures, stage, grade, age, residual disease, and BRCA1/BRCA2 germline mutations. Models 
were trained on a training dataset (TCGA samples; n = 273) and tested on the validation set (n = 83), including all samples with nonmissing data 
on all variables. The difference in outcome of the 3 predicted groups was tested using Kaplan-Meier survival analysis.
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more likely to have been optimally debulked, were not younger, 
and did not receive a different treatment regimen compared with 
patients for which there was concordance between molecular pre-
diction and poor clinical outcome. Interestingly, the amount of 
residual tumor after surgical debulking was independently related 
to prognosis in the CLOVAR Mesenchymal/CLOVAR poor prog-
nosis, CLOVAR Immunoreactive/CLOVAR poor prognosis, and 
CLOVAR Differentiated/CLOVAR poor prognosis groups (Figure 
2D and Supplemental Figure 4). Understanding the misclassifica-
tion of these patients requires further investigation and will assist 
in more accurate prediction of PFS.
Discussion
Here, we presented a detailed analysis of the TCGA ovarian car-
cinoma expression data in terms of the 4 expression subtypes 
previously reported by the TCGA Research Network and others 
(20, 23). In the combination of data types analyzed here, we sub-
stantially expanded the description of the previously observed 
Mesenchymal, Differentiated, Proliferative, and Immunoreactive 
subtypes (20, 23, 24). Importantly, we showed that individual 
HGS-OvCa samples often expressed multiple subtype signatures, 
and classification into different mutually exclusive subtypes may 
therefore be less informative than in other cancers, such as breast 
cancer and glioblastoma (25, 33). Infiltrating cells had a profound 
effect on the expression patterns of HGS-OvCa, and analysis of the 
expression profiles of purified HGS-OvCa tumor cells may iden-
tify novel signatures that are currently dominated by the tumor 
microenvironment signals.
The most relevant result of this study was the development of 
the CLOVAR subtype and CLOVAR survival signatures and their 
significant ability to predict outcome to therapy in the valida-
tion set. Tumor samples not present in the current study may be 
classified using data available at TCGA (https://tcga-data.nci.
nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/other/
publications/ov_exp/). The classifier effectively subdivided HGS-
OvCa patients in the large validation set into classes with differ-
ent survival profiles, independent of and complemented by known 
risk-associated variables, such as size of residual tumor and age. 
Previous attempts to identify poor prognosis groups typically 
separated patient cohorts into 2 groups, in which median sur-
vival of the poor survival category ranged 33–41 months (9, 10, 
29, 34). The large validation set allowed a detailed stratification 
resulting in identification of a subset of HGS-OvCa — compris-
ing 23% of the validation set — with 23 months median survival 
and 63% platinum therapy resistance. Pinpointing a subset of 
very poor prognosis patients prompts consideration of additional 
treatment options that may improve survival for these patients. 
Studies of recurrence and platinum response are affected by the 
different definitions of tumor recurrence being used at differ-
ent institutes (35). It is possible that greater prediction accuracy 
would be achieved when a standardized definition of progression 
is applied to all cases in the validation set. Investigation of incor-
rectly predicted cases, and factors such as BRCA pathway altera-
tions and CCNE1 amplifications, may reveal additional predictive 
factors (34, 36). Importantly, the prognostic model presented here 
needs to be validated prospectively before it may be translated to 
clinical use. A prospective study would be most revealing when 
assessing the predictive capacities of the CLOVAR signatures in 
conjunction with other prognostic factors, such as BRCA muta-
tion status (37, 38), age, grade, and residual disease. Concerns of 
prognosis are often among the first issues dealt with by ovarian 
cancer patients, and robust prognostic classification may aid in 
providing patients insight into this life-changing event.
The distinct biological characteristics of tumor samples associ-
ated with the each of the expression signatures suggest that the 
efficacy of experimental treatment modalities may be higher in 
some, but not all, prognostic groups. Clinical trials have been 
initiated in other cancers, such as glioma (trial ID RTOG 0825), 
that evaluate whether cases with high expression of Mesenchymal 
signatures are specifically sensitive to angiogenesis inhibitors. 
Similar efforts may be worthwhile in serous ovarian cancer, in 
which a subset of samples shows a mesenchymal phenotype. The 
effects of experimental therapies, such as dose-dense therapy or 
treatment with DNA damage repair inhibitors, may similarly be 
evaluated in the context of gene expression signatures (39–41). 
The CLOVAR signatures consist of 198 genes, making implemen-
tation using medium-throughput expression profiling platforms 
feasible. The association between the CLOVAR Mesenchymal/
CLOVAR Immunoreactive signature and CLOVAR survival sug-
gests an active role for the stromal tumor microenvironment 
in the pathogenesis of HGS-OvCa. Targeting of factors able to 
orchestrate immune response or stromal infiltration may there-
fore be used to design cancer therapies.
Studying HGS-OvCa in light of expression subtypes exposes 
features of ovarian carcinoma pathology that would otherwise 
have been neglected. The comprehensive CLOVAR framework pre-
sented here should provide a basis for improved understanding of 
ovarian carcinoma tumorigenesis that may ultimately lead to more 
effective treatments. Combining CLOVAR with clinically related 
features allows for robust survival classification. We expect that 
our findings will bring us closer to improving outcome in this dev-
astating disease by providing an effective prognostic strategy com-
bined with an approach to establishing new treatment modalities.
Methods
Patients and tumor samples. HGS-OvCa samples were collected and pro-
cessed through the TCGA Biospecimens Core Resource at the Interna-
tional Genomics Consortium; the same set of samples was used as in 
the prior TCGA ovarian carcinoma report (20). 489 ovarian tumors 
were selected according to the following criteria: (a) at least 70% tumor 
nuclei and less than 20% necrosis, (b) microarray quality controls within 
standards, and (c) high-quality data on each of the 3 gene expression 
platforms used. See Supplemental Table 1 for patient characteristics; 
all patient data have been deposited at the Data Coordinating Center of 
TGCA (http://cancergenome.nih.gov).
Microarray experiments and data processing. Gene expression profiles were 
established as described previously (20, 21, 25). In short, samples were 
assayed on 3 different microarray platforms: Affymetrix Human Exon 
1.0 ST GeneChips, Affymetrix HT-HG-U133A GeneChips, and custom 
designed Agilent 244,000 feature gene expression microarrays. Microarray 
labeling and hybridization protocols and quality control measures for 
each platform were performed as described elsewhere. Probes on all 3 plat-
forms were aligned to a transcript database consisting of RefSeq (36.1) and 
complete coding sequences from GenBank (version 161). Affymetrix HT-
HGU133A and Exon platforms were normalized and summarized using 
robust multichip average (RMA). Agilent data were lowess normalized and 
log transformed, and the mean was used to calculate gene level summaries. 
Gene-centric expression values were generated for every gene with at least 
5 (Affymetrix) or 3 (Agilent) perfect-match probes per gene, resulting in 
expression values for 12,042 (HT-HGU133A), 18,632 (Exon), and 18,623 
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(Agilent) genes, the intersect of the 3 platforms being 11,861 genes. All data 
are available at TCGA (https://tcga-data.nci.nih.gov/tcgafiles/ftp_auth/
distro_ftpusers/anonymous/other/publications/ov_exp/). The full data 
have been described in detail elsewhere (ref. 21 and TCGA Data Primer; 
https://wiki.nci.nih.gov/display/TCGA/TCGA+Data+Primer). Factor 
analysis was used to integrate these measurements together into a single 
estimate of the relative gene expression, as described previously (25, 42), 
and resulted in a unified gene estimate for each sample for 11,861 genes.
Subclass signature gene and gene set identification. The significance analysis 
of microarrays (SAM) method was used to identify marker genes and gene 
sets of each subtype. Each class was compared with the other 3 classes 
combined (43). We have provided both rank order and test statistics for 
all these analyses to allow independent confirmation of our findings on 
future analyses and datasets. The 200 most representative genes per TCGA 
expression cluster were selected by ranking genes by the F score (the mea-
sure used by SAM to indicate the difference in gene expression between 
2 groups) for a given gene (43). F scores that are further deviated from 
0 indicate a larger difference in gene expression. Signature genes could be 
either down- or upregulated. We limited our analysis to patients whose 
expression profiles clustered with a positive silhouette width (n = 413), a 
measure of how well a given expression profile represents the cluster of 
which it is a member. For marker gene set identification, SAM was applied 
on gene set activation scores.
Validation datasets. Class signatures were verified using expression pro-
files of 64 additional TCGA U133A expression profiles and publicly avail-
able stage II–III–IV ovarian serous carcinoma samples (GEO accession no. 
GSE9899; refs. 9, 10, 23, 29–31). Probes from Affymetrix HG-U133A or 
HG-U133plus2 GeneChip platforms were mapped to a transcript database 
and combined in 1 probe set per gene (44). Expression levels from the 4 
Affymetrix datasets were individually established using RMA and quantile 
normalization (45). The Operon Human version 3 dataset of Crijns et al. 
(9) was downloaded from GEO (accession no. GSE13876). For each gene 
within each sample, expression values were averaged for the 2 dye swap 
profiles. Probes measuring the same gene were averaged to get 1 expression 
value per gene and sample.
We used ssGSEA (see below) to generate gene set activation scores for 
each of the 4 signatures, after dimension reduction of the 800 genes in the 
combined signatures to the 100 genes included in the CLOVAR subtype sig-
natures to facilitate classification of new samples using medium-through-
put expression technologies (Supplemental Table 7). We used a Correla-
tion-based Feature Subset Selection algorithm available in Weka software, 
version 3.6.2 (46, 47). The search method was set to Best First search with 
default values. 10-fold cross validation was performed on the data. For each 
of the 10 runs, the algorithm output the best subset of genes it could find. 
Then, each of the genes was assigned a score based on how many subsets it 
was included in out of 10. We sorted the genes in descending order based on 
their scores: genes that appeared in all 10 subsets were at the top, followed 
by genes included in 9 subsets, and so on. To establish a 100-gene signature 
capable of predicting subtype, we selected the top 100 genes of this list that 
were additionally present in each of the 4 validation sets. The 100-gene set 
was used to train support vector machines for classification of samples in 
the validation set. Mean classification error when applying the 100-gene 
signature was 8% (CLOVAR Differentiated, 9%; CLOVAR Immunoreactive, 
9%; CLOVAR Mesenchymal, 6%; CLOVAR Proliferative, 8%), which indicates 
that classification can be performed with small error rates using the 100-
gene signature. Using the 100-gene signature and ssGSEA, we assigned 879 
expression profiles in the validation set to 1 of the 4 classes.
Prediction of survival. Using the 481 samples in the TCGA cohort for which 
survival annotation was supplied, each gene in the unified expression data-
set (n = 11,861) was assigned a univariate Cox P value for correlation with 
survival. The 100 genes with lowest Cox P values were used to calculate a 
prognostic t score, defined as the 2-sided t statistic comparing, within each 
tumor profile, the average of the poor prognosis mRNAs with the average 
of the good prognosis mRNAs (i.e., the t score for a given tumor being high 
when both the poor prognosis mRNAs in the signature were high and the 
good prognosis mRNAs were low) (48).
ssGSEA scores and gene sets. ssGSEA was used to generate gene set acti-
vation scores for the subtype, CLOVAR subtype, and CLOVAR survival 
expression signatures. For a given sample, gene expression values were 
rank normalized and rank ordered. The empirical cumulative distribu-
tion functions (ECDFs) of the genes in the signature and the remaining 
genes were calculated. A statistic was calculated by an integration of the 
difference between the ECDFs, which is similar to the one used in GSEA, 
but based on absolute expression rather than differential expression (25). 
The details of the procedure are as follows: for a given signature G of size 
NG and single sample S, of the dataset of N genes, the genes are replaced 
by their ranks according to their absolute expression L = {r1, r2, r3, . . . , rN} 
and rank ordered. An enrichment score ES(G,S) is obtained by a weighted 
sum (integration) of the difference between the ECDF of the genes in the 
signature PG and the ECDF of the remaining genes PNG.
     (Equation 1)
This calculation was repeated for each gene set in the database and each 
sample in the dataset. Notice that this quantity is signed, and that the 
exponent α = 3/4 adds a rank-associated weight.
The normalized ssGSEA scores are obtained in a similar manner as the 
normalized enrichment scores are obtained in standard GSEA (49). For 
a given sample, the ssGSEA normalized enrichment score is obtained by 
dividing the observed raw ssGSEA by the mean of the raw ssGSEA scores 
obtained for randomized versions of the gene set’s tags. This normaliza-
tion uses the mean of the positive/negative permutation raw ssGSEA 
scores according to the sign (positive/negative) of the observed ssGSEA 
score. The normalization adjusts the ssGSEA scores to be in the same scale 
regardless of the size of the gene set and is motivated by the asymptotic 
scaling of the Kolmogorov-Smirnov statistic as a function of gene set size 
(see ref. 49 and Supplemental Methods).
Gene sets were downloaded from the Molecular Signatures Database 
(collection C2, version 3.0; http://www.broadinstitute.org/msigdb; 
ref. 28) and complemented by the Oncogene Pathway Activation data-
base, a manually curated collection of 296 gene sets defined from GEO 
gene expression datasets and the biomedical literature as representing 
oncogene activation or tumor suppressor dysregulation (49). These 2 col-
lections were augmented with additional “combined” signatures for the 
ones that have both upregulated (UP) and downregulated (DN) versions, 
producing a total of 7,553 gene sets. Subtypes were annotated using gene 
sets (see Supplemental Methods).
Subclass classification. In order to establish the subtype of tumor samples 
in the validation set, CLOVAR subtype gene set scores were generated 
using ssGSEA. Scores were normalized to allow comparability between 
datasets from different expression platforms as described above. Of the 
TCGA samples originally clustering in the Immunoreactive subtype with 
a positive silhouette width, the lowest CLOVAR Immunoreactive signa-
ture normalized ssGSEA score was determined to be 0.63. Similarly, of 
the TCGA samples originally clustering in the Mesenchymal subtype, the 
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lowest CLOVAR Mesenchymal signature ssGSEA score was determined 
to be 0.56. All samples in the validation set that expressed the CLOVAR 
Immunoreactive/CLOVAR Mesenchymal signature above these thresholds 
were assigned to the Immunoreactive (n = 280) and Mesenchymal (n = 282) 
groups per the higher of the 2 normalized ssGSEA scores. Samples in the 
validation set were assigned to 1 of the 4 classes per the highest of the 4 
normalized ssGSEA scores. Normalized ssGSEA scores were additionally 
determined for the CLOVAR survival gene set, and cases were assigned to 
CLOVAR poor prognosis and CLOVAR good prognosis groups based on a 
score threshold of 0.5.
Associations of gene expression signatures with mutations and copy number altera-
tions. Segmented copy number profiles from the Agilent 244K platform 
were available for 489 ovarian carcinoma samples and matched normal 
controls. Preprocessing was performed using the GISTIC2.0 pipeline, as 
described previously (20, 50). All genes that were reported to be altered in 
at least 10 of 489 cases (1,437 deleted, 8,793 amplified) were categorized 
using sample-specific thresholds as previously described (21) into 1 of 3 
levels: (a) deep deletion, (b) neutral copy number, and (c) high gain. Dele-
tions and gains were tested independently of each other.
Nearly complete exon sequence data on 18,500 genes and 316 samples 
was used to report 19,356 somatic mutations in the previously reported 
integrated genomic analysis of ovarian carcinoma (20).
Association of copy number alterations and mutations with gene expres-
sion signatures was determined by comparing the normalized gene set 
scores of altered and nonaltered samples using a paired t test and using the 
Hochberg method implemented in p.adjust (http://www.R-project.org) for 
controlling the family-wise error rate.
Expression profiling of normal fallopian tube. Fresh Fallopian tube fim-
bria specimens were obtained from the Brigham and Women’s Hospital 
Department of Pathology with IRB approval. Only fimbria from non-
oncologic gynecological procedures were used. The tissue was incubated 
in a dissociation medium composed of MEM (Cellgro) supplemented 
with 3.5 mg/ml Pronase (Roche Diagnostics) and 0.25 mg/ml DNase 
(Sigma-Aldrich) for 48–72 hours in 4°C with constant mild agitation as 
previously described (51). The dissociated epithelial cells were harvested by 
centrifugation cultured in growth medium (DMEM/Ham’s F12, 1:1 [Cell-
gro], supplemented with 2% serum substitute Ultroser G [Pall Corp.] and 
1% penicillin/streptomycin [PS; Invitrogen]) on culture dishes treated with 
human collagen IV (Sigma-Aldrich; 0.06 mg/ml in water). RNA from the 
cells was extracted using TRIzol reagent (Invitrogen) followed by RNeasy 
clean-up kit (Qiagen). Expression profiling was performed using Human 
Genome U133 Plus 2.0 microarray (Affymetrix).
Histopathological features. For a subset of 98 TCGA ovarian carcinomas, 
a single slide stained for H&E was scanned at ×20 using Aperio XS slide 
scanner (Aperio). At low-power magnification, the extent of demoplastic 
stromal reaction was recorded as extensive if the tumor cell/stroma ratio 
was less than 2:1, i.e., the desmoplastic stroma accounted for at least one-
third of the tumor area. Typically, tumor cells were seen in a nested pattern 
surrounded by abundant stroma. At high-power magnification, 10 fields 
were counted for the presence of intratumoral lymphocytes within the cel-
lular borders of tumor cells. Prominent intratumoral lymphocytosis was 
defined as >10 lymphocytes per average high-power field.
Computation of risk scores. To evaluate the CLOVAR survival signature for 
outcome prediction, 3 different models were considered. The first model 
included 2 covariates, CLOVAR survival score and CLOVAR subtype signa-
tures (Figure 3A), grouping all samples into 3 categories: CLOVAR Immu-
noreactive, CLOVAR Mesenchymal, and others. In order to test whether 
including additional prognostic factors would improve the predictions, 
the first model was extended (Figure 3B) by adding the following 4 poten-
tial prognostic factors to the CLOVAR survival signature model: (a) stage, 
(b) grade, (c) age, and (d) residual disease. Next, the addition of “presence 
of BRCA1/BRCA2 germline mutations” to the second model was evaluated 
(Figure 3C). For this purpose, the third model included CLOVAR survival 
score, CLOVAR subtype signatures, stage, grade, age, residual disease, and 
presence of BRCA1/BRCA2 germline mutations as predictors of survival. 
To make a fair comparison among models, the same set of samples was 
used for all 3 models (TCGA training set, n = 273; validation set, n = 83), 
with nonmissing data on all variables. In each model, the risk score was 
computed for each patient, defined as a linear combination of predictor 
variables weighted by their respective Cox regression coefficients. Patients 
in the training set were then classified into good, intermediate, and poor 
outcome groups according to the risk scores, using tertile scores of the 
training set as cutoffs. Similarly, patients in the validation set were split 
into 3 risk groups using the same cutoffs as used for the training set. Dif-
ferences in survival times were tested using the log-rank test.
Statistics. Statistical analysis was performed using the R statistical com-
puting environment. The SAM method was used to identify marker genes 
and gene sets of each subtype, ranking genes and gene sets by F test score 
and with a q value less than 0.05 considered significant. Log-rank likeli-
hood models and Cox proportional hazards regression models were used 
to test for differences in survival, and a P value of less than 0.05 was consid-
ered significant. A paired 2-sided Student’s t test was used to test the signif-
icance of association between expression subtype and genomic alterations. 
P values were corrected for multiple testing using the Hochberg method 
for controlling the family-wise error rate. Corrected P values less than 0.05 
were considered significant.
Study approval. Ovarian cancer samples were collected and processed 
through the TCGA Biospecimens Core Resource at the International 
Genomics Consortium (Phoenix, Arizona, USA), as described elsewhere 
(20). All specimens were collected using IRB-approved protocols and were 
deidentified to ensure patient confidentiality. All data used in this study 
have been published previously, or through TCGA.
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